Topic Review
Arginine Signaling and Cancer Metabolism
Arginine is an amino acid critically involved in multiple cellular processes including the syntheses of nitric oxide and polyamine, and is a direct activator of mTOR, a nutrient sensing kinase strongly implicated in carcinogenesis. In this review, we will discuss arginine as a signaling metabolite, arginine’s role in cancer metabolism, arginine as an epigenetic regulator, arginine as an immunomodulator, and arginine as a therapeutic target. The different cell killing mechanisms associated with various cancer types will also be described.
  • 37.5K
  • 23 Feb 2023
Topic Review
Clavicular Malignancies
The clavicle, or collar bone, is a long (6 inches in adults), tubular, S-shaped bone that is subcutaneous throughout and can be considered “special” for several reasons. It is the first bone to ossify in the embryo, with its two first ossification centers developing between the fifth and sixth weeks of gestation. Malignant clavicular tumors present with local pain, a palpable firm mass or pathological bone fracture, or with the clinical symptoms of the primary tumor (in cases of metastasis).
  • 11.4K
  • 20 Jul 2022
Topic Review
Monochromatic X-rays
Monochromatic X-ray has a single energy level in contrast to white X-rays used in conventional radiation therapy. Irradiation of high Z elements such as gadolinium, gold and silver with a monochromatic X-ray can result in photoelectric effects that includes the release of the Auger electrons that have strong cell killing effect. To apply this principle to cancer therapy, various nanoparticles loaded with high Z elements have been developed that enabled high Z elements to be delivered to tumor. The recent addition is gadolinium-loaded mesoporous silica nanoparticle (Gd-MSN). Tumor spheroids have been used as a convenient tumor model to demonstrate that monochromatic X-rays with energy level at or higher than the K-edge energy of gadolinium can destruct tumor mass that has Gd-MSN distributed throughout tumor spheroids.
  • 9.8K
  • 22 Jul 2020
Topic Review
Peculiarities of Tumor Cell Metabolism for Cancer Treatment
In tumor cells, ketolysis “via” succinyl-CoA: 3-oxoacid-CoAtransferase (SCOT) and acetyl-CoA acetyltransferase 1 (ACAT1) is a major source of mitochondrial acetyl-CoA. Active ACAT1 tetramers stabilize by tyrosine phosphorylation, which facilitates the SCOT reaction and ketolysis. Tyrosine phosphorylation of pyruvate kinase PK M2 has the opposite effect, stabilizing inactive dimers, while pyruvate dehydrogenase (PDH), which is already inhibited by phosphorylation, is acetylated by ACAT1 and is doubly locked. This closes the glycolytic supply of acetyl-CoA. In addition, since tumor cells must synthesize fatty acids to create new membranes, they automatically turn off the degradation of fatty acids into acetyl-CoA (“via” the malonyl-CoA brake for the fatty acid carnityl transporter). Thus, inhibiting SCOT the specific ketolytic enzyme and ACAT1 should hold back tumor progression. However, tumor cells are still able to take up external acetate and convert it into acetyl-CoA in their cytosol “via” an acetyl-CoA synthetase, which feeds the lipogenic pathway; additionally, inhibiting this enzyme would make it difficult for tumor cells to form new lipid membrane and survive.
  • 8.7K
  • 21 Feb 2023
Topic Review
Tumoroid
The term “tumoroid” means “tumor-like organoid”: tumoroids typically derive from primary tumors harvested from oncological patients and they can mimic human tumor microenvironment (TME); nowadays, they are considered a promising tool for cost-effective studies on novel anticancer drugs to be used in precision medicine in the field of oncology.
  • 4.7K
  • 18 Jun 2024
Topic Review
Molecular Mechanisms of Homologous Recombination
Homologous recombination (HR) is a fundamental evolutionarily conserved process that plays prime role(s) in genome stability maintenance through DNA repair and through the protection and resumption of arrested replication forks. HR promotes the exchange between homologous DNA sequences resulting in a novel combination of the genetic material. Therefore, HR is essential in genome stability maintenance but also plays an important role in genome diversity; such as in the case of meiosis. Many HR genes are deregulated in cancer cells. Notably, the breast cancer genes BRCA1 and BRCA2, two important HR players, are the most frequently mutated genes in familial breast and ovarian cancer. 
  • 4.4K
  • 28 Apr 2021
Topic Review
Antibody–Drug Conjugates
An armed antibody or antibody–drug conjugate (ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, to allow ADCs to get a little closer to the magic bullet imagined by Paul Ehrlich at the beginning of the 20th century.
  • 4.2K
  • 10 Apr 2021
Topic Review
Treatment Algorithm for Cancerous Wounds
Cancerous wound can be defined as non-healing compound chronic painful wound that arises from cancers and due to increased necrosis and infection, the quantity of malodorous discharge is highly increased. In advanced cancer stage the incidence of cancerous wounds is about 5%, and the estimated life expectancy is not more than 6 to 12 months. 
  • 4.2K
  • 11 Mar 2022
Topic Review
Universal Model of Cancer Transformation and Development
As a phenomenon, cancer is a disease related to multicellular evolution, i.e., cancer in general is understood to be a failure of the multicellular systems and is considered a reversal to unicellularity. Cancer cells are like unicellular organisms that benefit from ancestral-like traits. As a disease, cancer can be interpreted as (a) a destruction of cooperative behaviors underlying multicellular evolution, (b) a disruption of molecular networks established during the emergence of multicellularity or (c) an atavistic state resulting from reactivation of primitive programs typical of the earliest unicellular species. From this point of view and in accordance with the layered model of evolution of cellular functionalities, cancer transformation can occur as a result of huge disturbances or the destruction of functionalities that are located in the multicellular layer.
  • 4.0K
  • 06 May 2022
Topic Review
Post-Translational Modification
Post-translational modifications (PTMs) add a layer of complexity to the proteome through the addition of biochemical moieties to specific residues of proteins, altering their structure, function and/or localization. Mass spectrometry (MS)-based techniques are at the forefront of PTM analysis due to their ability to detect large numbers of modified proteins with a high level of sensitivity and specificity.
  • 4.0K
  • 29 Apr 2021
Topic Review
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality worldwide. Most patients are diagnosed with advanced disease, limiting their options for treatment. While current treatments are adequate for lower staged disease, available systemic treatments are limited, with marginal benefit at best. The below section reviews the incidence, prevalence, healthcare associated cost, and etiologies of HCC. In addition, an overview of the classification, treatment algorithm, and treatment modalities are provided.
  • 3.8K
  • 07 Jan 2021
Topic Review
Satellitosis in Neurological Disease
The secondary structures of Scherer commonly known as perineuronal and perivascular satellitosis have been identified as a histopathological hallmark of diffuse, invasive, high-grade gliomas. They are recognised as perineuronal satellitosis when clusters of neoplastic glial cells surround neurons cell bodies and perivascular satellitosis when such tumour cells surround blood vessels infiltrating Virchow–Robin spaces. 
  • 3.4K
  • 27 Jan 2021
Topic Review
EBV Lytic Induction therapy
Epstein-Barr virus (EBV) lytic induction therapy is an emerging virus-targeted therapeutic approach that exploits the presence of EBV in tumor cells to confer specific killing effects against EBV-associated malignancies. Efforts have been made in the past years to uncover the mechanisms of EBV latent-lytic switch and discover different classes of chemical compounds that can reactivate the EBV lytic cycle. Despite the growing list of compounds showing potential to be used in the lytic induction therapy, only a few are being tested in clinical trials with varying degrees of success. This review will summarize the current knowledge on EBV lytic reactivation, the major hurdles of translating the lytic induction therapy into clinical settings and highlight some potential strategies in the future development of this therapy for EBV-related lymphoid and epithelial malignancies.
  • 3.3K
  • 28 Oct 2020
Topic Review
Cancer-Associated Thrombosis Patients with Glioblastoma
Cancer is an independent risk factor for the development of venous thromboembolism (VTE). Glioblastomas are amongst cancer types with the most thrombogenic potential and patients are at a particularly high risk of VTE with an incidence up to 20–30% per year. Currently, major efforts are underway to gain novel insights into risk factors and pathomechanisms to provide a better understanding of development of VTE in patients with primary brain tumors. Treatment of VTE requires therapeutic anticoagulation, which accordingly to recently-published guidelines should be performed using low molecular weight heparin or, in case of low bleeding risk, using a direct oral anticoagulant. However, this can be very challenging due to an increased risk of intracranial hemorrhage in this patient group. Furthermore, limited data are available on the subgroup of patients with primary brain tumors.
  • 3.2K
  • 13 Oct 2020
Topic Review
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are heterogeneous cells derived from bone marrow. They are precursors of dendritic cells, macrophages and/or granulocytes. They have the ability to significantly inhibit immune cell responses.
  • 3.2K
  • 27 Oct 2020
Topic Review
P53 Protein famliy
p53 and p73 are critical tumor suppressors that are often inactivated in human cancers through various mechanisms. Owing to their high structural homology, the proteins have many joined functions and recognize the same set of genes involved in apoptosis and cell cycle regulation. p53 is known as the ‘guardian of the genome’ and together with p73 forms a barrier against cancer development and progression. The TP53 is mutated in more than 50% of all human cancers and the germline mutations in TP53 predispose to the early onset of multiple tumors in Li–Fraumeni syndrome (LFS), the inherited cancer predisposition. In cancers where TP53 gene is intact, p53 is degraded. Despite the ongoing efforts, the treatment of cancers remains challenging. Presently, the endeavors focus on reactivating p53 exclusively, neglecting the potential of the restoration of p73 protein for cancer eradication. Taken that several small molecules reactivating p53 failed in clinical trials, there is a need to develop new treatments targeting p53 proteins in cancer. This review outlines the most advanced strategies to reactivate p53 and p73 and describes drug repurposing approaches for the efficient reinstatement of the p53 proteins for cancer therapy.
  • 3.1K
  • 21 Oct 2020
Topic Review
Bovine Colostrum in the Treatment of Cancer
Bovine colostrum (BC) has attracted the interest of numerous researchers investigating its anti-cancer potential in humans. Dressings loaded with BC are beneficial in treating chronic wounds and diabetic foot ulcers. Lactoferrin, a glycoprotein with potent anti-oxidant, anti-inflammatory, anti-cancer, and anti-microbial effects, is abundant in BC. The BC pills successfully promote the regression of low-grade cervical intraepithelial neoplasia when administered intravaginally. The biological, genetic, and molecular mechanisms driving BC remain to be determined. Oral BC supplements are generally well-tolerated, but some flatulence and nausea may happen. 
  • 3.0K
  • 21 Dec 2022
Topic Review
Gastric Cancer Classification
Gastric cancer(GC) is the fourth most common cause of cancer-related mortalities worldwide. The incidence rate of GC rises progressively with age, the median age at diagnosis is 70 years. GC is a multifactorial disease, and both environmental and genetic factors have a role in its aetiology. Regarding the age of diagnosis, it is divided into early-onset gastric carcinoma (EOGC; 45 years or younger) and conventional GC (CGC; older than 45). EOGC relies mostly on genetic factors and therefore provides a unique model to study genetic alterations in GCs.
  • 2.9K
  • 27 Oct 2020
Topic Review
Essential-thrombocythemia and Acquired von-Willebrand Syndrome
Over the past decade, new insights have emerged on the pathophysiology of essential thrombocythemia (ET), its clinical management, and associated thrombohemostatic disturbances. Here, we review the latest diagnostic and risk stratification modalities of ET and its therapeutics. Moreover, we discuss the clinical evidence-based benefits, deriving from major clinical trials, of using cytoreductive therapy and antiplatelet agents to lower the risk of fatal vascular events. Also, we focus on the condition of extreme thrombocytosis (>1000 × 109/L) and bleeding risk, the development and pathogenesis of acquired von Willebrand syndrome, and the clinical approach to this paradoxical scenario in ET.
  • 2.7K
  • 20 Oct 2020
Topic Review
Antiparasitic Mebendazole for the Treatment of Brain Cancers
Cancer ranks as a leading cause of death and a significant barrier to increasing life expectancy in every country. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before age 70 in 112 of 183 countries and ranks third or fourth in 23 countries. Tumor treatments usually consist of chemotherapy, radiotherapy, surgery, targeted therapy, immunotherapy, and endocrine therapy that can be used individually or in combination, depending on the stage and type of tumor and diagnosis. Several factors reduce the practical improvement of a cancer patient’s prognosis. Drug-untreatable targets, chemoresistance, tumor heterogeneity, and metastases formation are significant barriers to the effective cure of cancer patients. Despite intense preclinical and clinical research efforts, the survival rate of patients suffering from the most aggressive cancer types has not yet improved, mainly due to therapeutic failure. Moreover, nearly all anticancer medications on the market have serious adverse effects; therefore, new, safer anticancer drugs are desirable.
  • 2.7K
  • 19 Jan 2023
  • Page
  • of
  • 128
ScholarVision Creations